• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients

tetano

Editor, Senior Moderator
iScience


. 2021 May 1;102489.
doi: 10.1016/j.isci.2021.102489. Online ahead of print.
Comparative Analysis of Antibodies to SARS-CoV-2 between Asymptomatic and Convalescent Patients


Connor J Dwyer[SUP] 1 [/SUP], Colleen A Cloud[SUP] 1 [/SUP], Cindy Wang[SUP] 1 [/SUP], Philip Heidt[SUP] 1 [/SUP], Paramita Chakraborty[SUP] 1 [/SUP], Tara F Duke[SUP] 1 [/SUP], Shannon McGue[SUP] 2 [/SUP], Braxton Jeffcoat[SUP] 1 [/SUP], Jaclyn Dunne[SUP] 1 [/SUP], Logan Johnson[SUP] 1 [/SUP], Seungho Choi[SUP] 1 [/SUP], Georges J Nahhas[SUP] 3 [/SUP], Amy S Gandy[SUP] 4 [/SUP], Nikolina Babic[SUP] 5 [/SUP], Frederick S Nolte[SUP] 5 [/SUP], Philip Howe[SUP] 6 [/SUP], Besim Ogretmen[SUP] 6 [/SUP], Vamsi K Gangaraju[SUP] 6 [/SUP], Stephen Tomlinson[SUP] 7 [/SUP], Brian Madden[SUP] 8 [/SUP], Tracy Bridges[SUP] 8 [/SUP], Patrick A Flume[SUP] 2 [/SUP], John Wrangle[SUP] 2 [/SUP], Mark P Rubinstein[SUP] 1 [/SUP], Prabhakar K Baliga[SUP] 1 [/SUP], Satish N Nadig[SUP] 1 [/SUP], Shikhar Mehrotra[SUP] 1 [/SUP]



Affiliations

Abstract

The SARS-CoV-2 viral pandemic has induced a global health crisis, which requires more in-depth investigation into immunological responses to develop effective treatments and vaccines. To understand protective immunity against COVID-19, we screened over 60,000 asymptomatic individuals in the Southeastern United States for IgG antibody positivity against the viral spike protein, and approximately three percent were positive. Of these three percent, individuals with the highest anti-S or anti-RBD IgG level showed a strong correlation with inhibition of ACE2 binding and cross-reactivity against non-SARS-CoV-2 coronavirus S-proteins. We also analyzed samples from 94 SARS-CoV-2 patients and compared them to asymptomatic individuals. SARS-CoV-2 symptomatic patients had decreased antibody responses, ACE2 binding inhibition, and antibody cross-reactivity. Our study shows that healthy individuals can mount robust immune responses against SARS-CoV-2 without symptoms. Further, IgG antibody responses against S and RBD may correlate with high inhibition of ACE2 binding in individuals tested for SARS-CoV-2 infection or vaccination.

Keywords: IgA; IgG; IgM; SARS-CoV-2.
 
Back
Top Bottom